# Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor

> **NCT05009966** · PHASE1 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 272 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Gastric Cancer (GC)
- Gastroesophageal Junction (GEJ) Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** SYSA1801 for injection

## Key facts

- **NCT ID:** NCT05009966
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-16
- **Primary completion:** 2023-12
- **Final completion:** 2024-06
- **Target enrollment:** 272 (ESTIMATED)
- **Last updated:** 2021-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05009966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05009966, "Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05009966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*